Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
novartis.com

See what CB Insights has to offer

Investments

53

Portfolio Exits

28

Partners & Customers

10

Service Providers

1

About Novartis

Novartis (NYSE: NVS) is a global healthcare company that provides solutions to address the evolving needs of patients worldwide. Focusing solely on healthcare, Novartis offers a diversified portfolio to meet these needs including medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools, and consumer health products.

Novartis Headquarter Location

Forum 1 Novartis Campus

Basel, 4056,

Switzerland

+41 61 324 11 11

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Novartis

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Novartis in 5 Expert Collections, including Digital Health.

D

Digital Health

393 items

Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)

S

Synthetic Biology

382 items

D

Diabetes

1,750 items

M

Medical Devices

412 items

https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.

H

Health Monitoring & Diagnostics

701 items

Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting

Novartis Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Novartis Rank

Latest Novartis News

Novartis working on pan-coronavirus oral treatment, CEO says

Dec 6, 2021

Author of the article: Article content Novartis hopes to still play a role in the development of COVID-19 treatments with research ongoing for a pill that could work broadly against coronaviruses, not just the one that causes COVID-19, chief executive Vas Narasimhan told Reuters. In an interview following his recent presentation at Total Health last week, the head of the Swiss drugmaker pointed to Novartis’ manufacturing support to COVID-19 vaccine and drug makers when asked if it had been on the sidelines during the pandemic. We apologize, but this video has failed to load. Try refreshing your browser, or Advertisement Article content “Now I would have loved for some of our own clinical trials to have worked out, but they didn’t. I mean, that’s part of the deal,” Narasimhan said. “I think we as a sector have collaborated extremely well to ultimately be the industry that enabled this pandemic over time to eventually be under control.” Many drugmakers including AstraZeneca sold treatments at cost during the pandemic, but are now looking to start making profits as some parts of the world reopen. “I think in order to have companies invest in the long run for pandemic preparedness, there has to be a reasonable economic benefit to the companies,” Narasimhan said. “I think that has to be clear and understood by all involved.” Novartis last year had signed a deal with Molecular Partners to develop two DARPin-based therapies as potential COVID-19 treatments. A new readout from studies of one of those treatments is expected in January, and the duo will then decide on next steps based on that data, Narasimhan said. The company last week said it was confident of delivering annual revenue growth of 4% or higher until 2026, as it banks on multi-billion dollar sales of experimental and approved drugs including arthritis and psoriasis medicine Cosentyx. (Reporting by Pushkala Aripaka in Bengaluru, Editing by Louise Heavens) Share this article in your social network Share this Story: Novartis working on pan-coronavirus oral treatment, CEO says

Novartis Investments

53 Investments

Novartis has made 53 investments. Their latest investment was in Kedalion Therapeutics as part of their Series B on November 11, 2021.

CBI Logo

Novartis Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/15/2021

Series B

Kedalion Therapeutics

Yes

1

11/9/2021

Series A

Mekonos

$25M

No

4

9/22/2021

Series C

Credence MedSystems

$39.9M

No

2

8/11/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

7/14/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/15/2021

11/9/2021

9/22/2021

8/11/2021

7/14/2021

Round

Series B

Series A

Series C

Series A

Series C

Company

Kedalion Therapeutics

Mekonos

Credence MedSystems

Subscribe to see more

Subscribe to see more

Amount

$25M

$39.9M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

4

2

10

10

Novartis Portfolio Exits

28 Portfolio Exits

Novartis has 28 portfolio exits. Their latest portfolio exit was Rani Therapeutics on July 30, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/30/2021

IPO

$991

3

7/23/2021

IPO

$991

2

6/22/2021

Acq - Pending

$991

5

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

7/30/2021

7/23/2021

6/22/2021

00/00/0000

00/00/0000

Exit

IPO

IPO

Acq - Pending

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

3

2

5

10

10

Novartis Acquisitions

31 Acquisitions

Novartis acquired 31 companies. Their latest acquisition was Arctos Medical on September 21, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/21/2021

Series A

$6.1M

Acquired

5

12/17/2020

Series B - III

$991

$55M

Acquired

18

10/29/2020

Seed VC

$991

$0.93M

Acquired

4

4/20/2020

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

11/25/2019

PIPE

Subscribe to see more

$991

$99M

Subscribe to see more

10

Date

9/21/2021

12/17/2020

10/29/2020

4/20/2020

11/25/2019

Investment Stage

Series A

Series B - III

Seed VC

Seed VC

PIPE

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Total Funding

$6.1M

$55M

$0.93M

$99M

$99M

Note

Acquired

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

5

18

4

10

10

Novartis Partners & Customers

10 Partners and customers

Novartis has 10 strategic partners and customers. Novartis recently partnered with Dunad on November 11, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

11/2/2021

Licensee

Dunad

United Kingdom

Dunad Therapeutics could earn $1.3bn add-ons from Novartis collaboration

Professor Patrick Gunning , Dunad Therapeutics 's co-founder , acting CEO and chief scientific officer said : `` We are thrilled to have entered this collaboration with Novartis , which has already established a world leading position in the protein degradation space .

6

10/21/2021

Partner

BioNTech

Germany

Novartis signs new agreement with BioNTech for COVID-19 vaccine fill and finish

Novartis has signed a new initial agreement with BioNTech for COVID-19 vaccine manufacturing : with its sterile manufacturing facilities in Ljubljana , Slovenia , to fill at least 24 million doses in 2022 .

2

10/12/2021

Partner

Innodem Neuroscience

Canada

1

9/22/2021

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

9/19/2021

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

11/2/2021

10/21/2021

10/12/2021

9/22/2021

9/19/2021

Type

Licensee

Partner

Partner

Partner

Partner

Business Partner

Dunad

BioNTech

Innodem Neuroscience

Country

United Kingdom

Germany

Canada

Subscribe to see more

Subscribe to see more

News Snippet

Dunad Therapeutics could earn $1.3bn add-ons from Novartis collaboration

Professor Patrick Gunning , Dunad Therapeutics 's co-founder , acting CEO and chief scientific officer said : `` We are thrilled to have entered this collaboration with Novartis , which has already established a world leading position in the protein degradation space .

Novartis signs new agreement with BioNTech for COVID-19 vaccine fill and finish

Novartis has signed a new initial agreement with BioNTech for COVID-19 vaccine manufacturing : with its sterile manufacturing facilities in Ljubljana , Slovenia , to fill at least 24 million doses in 2022 .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

6

2

1

10

10

Novartis Service Providers

1 Service Provider

Novartis has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acq - P2P

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Novartis Team

117 Team Members

Novartis has 117 team members, including current Chief Executive Officer, George Gunn.

Name

Work History

Title

Status

Jacob LaPorte

Founder

Current

George Gunn

Chief Executive Officer

Current

Joseph Jimenez

Chief Executive Officer

Current

Jerry Karabelas

Chief Executive Officer

Current

Remo Inglin

ICN Pharmaceuticals

Chief Financial Officer

Current

Name

Jacob LaPorte

George Gunn

Joseph Jimenez

Jerry Karabelas

Remo Inglin

Work History

ICN Pharmaceuticals

Title

Founder

Chief Executive Officer

Chief Executive Officer

Chief Executive Officer

Chief Financial Officer

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.